Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of TPN171H in Renal Insufficiency
NCT05208814Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sildenafil in pulmonary arterial hypertension (PAH) and erectile dysfunction (ED) (2 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Area under the curve at 120 hours, Time to maximum plasma concentration at 120 hours and 6 more. Started Mar 2022; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT05208814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208814.